SLRX - Salarius Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
11.32M
Enterprise Value 3
9.12M
Trailing P/E
N/A
Forward P/E 1
-1.40
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
3.69
Price/Book (mrq)
1.07
Enterprise Value/Revenue 3
2.97
Enterprise Value/EBITDA 6
-2.01

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-64.03%
S&P500 52-Week Change 325.86%
52 Week High 324.4500
52 Week Low 32.7000
50-Day Moving Average 33.7102
200-Day Moving Average 36.3962

Share Statistics

Avg Vol (3 month) 366.96k
Avg Vol (10 day) 366.57k
Shares Outstanding 54.07M
Float 2.98M
% Held by Insiders 128.24%
% Held by Institutions 16.32%
Shares Short (Dec 30, 2019) 4105.69k
Short Ratio (Dec 30, 2019) 40.87
Short % of Float (Dec 30, 2019) 43.20%
Short % of Shares Outstanding (Dec 30, 2019) 42.60%
Shares Short (prior month Nov 28, 2019) 468.36k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:25
Last Split Date 3Jul 21, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin -200.50%
Operating Margin (ttm)-148.62%

Management Effectiveness

Return on Assets (ttm)-27.22%
Return on Equity (ttm)-109.67%

Income Statement

Revenue (ttm)3.06M
Revenue Per Share (ttm)2.54
Quarterly Revenue Growth (yoy)86.50%
Gross Profit (ttm)663.73k
EBITDA -4.54M
Net Income Avi to Common (ttm)-6.2M
Diluted EPS (ttm)-5.1360
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)4M
Total Cash Per Share (mrq)0.98
Total Debt (mrq)749.16k
Total Debt/Equity (mrq)7.69
Current Ratio (mrq)1.11
Book Value Per Share (mrq)2.59

Cash Flow Statement

Operating Cash Flow (ttm)-8.56M
Levered Free Cash Flow (ttm)-2.95M